Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body

Summary

This Phase 1 study in healthy adults looks at whether sevabertinib changes how the body handles metformin. The study is based on the idea that sevabertinib may block kidney transporters (proteins that move medicines) called MATE1 and MATE2-K, which help remove metformin from the body. Each participant receives a single dose of metformin alone, and later receives sevabertinib for several days and then takes metformin again while still taking sevabertinib. The study aims to learn how metformin, gets into, moves through, and out of the body when it is administered with sevabertinib.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Healthy Participants

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 55 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Bayer

Last updated on ClinicalTrials.gov

October 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites